Arcutis Biotherapeutics: Soaring On Q3 Earnings - Further Upside Likely (Upgrade) (ARQT)

Group 1 - Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) stock increased by 30%, reaching a price of $26, marking its highest value since August 2022 following the release of its Q3 earnings [1] - The company is part of the biotech, pharma, and healthcare industries, which are currently experiencing significant market movements [1] Group 2 - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, and product sales forecasts for major pharmaceutical companies [2] - The group also offers integrated financial statements, discounted cash flow analysis, and market-by-market analysis [2]